Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. · ¶31

Applying these standards to the complaint here, Amarin fails to allege “more than a sheer possibility” that Hikma actively induced infringement of Amarin’s CV-indication patents. Iqbal, 556 U. S., at 678. Amarin’s allegations, whether viewed together or separately, fail to establish that Hikma took any affirmative steps to encourage infringement.

slip opinion
Source edition
Passage preview. Read in context for the complete text, notes and references.